Work with thought leaders and academic experts in neurodegeneration

Companies can benefit from working with academic researchers in the field of Neurodegeneration in several ways. These experts can provide valuable insights and knowledge to develop new treatments and therapies for neurodegenerative diseases. They can also contribute to the development of diagnostic tools and biomarkers for early detection and monitoring of these diseases. Additionally, academic researchers can help companies in conducting preclinical and clinical trials, as well as analyzing and interpreting data. Their expertise can also be utilized in the development of neuroprotective strategies and personalized medicine approaches. Overall, collaborating with Neurodegeneration experts can accelerate research and development efforts, enhance scientific credibility, and open up new opportunities for innovation and growth.

Researchers on NotedSource with backgrounds in neurodegeneration include Joshua adekunle Babalola, Ph.D., and Janel Johnson Ph.D..

Janel Johnson Ph.D.

New York, New York, United States of America
Molecular Geneticist experienced in Neuroscience, Oncology, Immunology, and Intellectual Property
Most Relevant Research Interests
Neurodegeneration
Other Research Interests (4)
Genetics
Amyotrophic Lateral Sclerosis
Frontotemporal Demetia
Next Generation Sequencing
About
Dr. Janel Johnson is a distinguished Biologist with over 20 years of dedicated academic research focused on the genetics of Neuroscience, Oncology, and Immunology. She obtained her BA in Biology from The Johns Hopkins University in 1999, following which she conducted groundbreaking research at The Johns Hopkins University Sidney Kimmel Cancer Center. Here, she explored the selective cytotoxic effects of a tyrosine kinase inhibitor in a transgenic mouse model of acute myeloid leukemia. Transitioning to The National Institutes of Health (NIH), Dr. Johnson continued her impactful career, making significant contributions to the study of Alzheimer’s disease and Parkinson's disease genetics. Sponsored by the NIH, she pursued her MPhil and PhD in Molecular Genetics at University College London, focusing on unraveling the genetic basis of Spinocerebellar Ataxia (SCA) and Childhood Motor Neuron Disease. Notably, her research elucidated that mutations in the Tau Tubulin Kinase 2 gene cause SCA Type 11, and she identified riboflavin transporter mutations as the underlying cause of Childhood Motor Neuron Disease, highlighting the potential for vitamin B2 supplementation as a therapeutic intervention. Furthering her postgraduate research at NIH, Dr. Johnson delved into investigating the genetics of Amyotrophic Lateral Sclerosis (ALS) and related motor neuron disorders. Her seminal findings uncovered that mutations in genes such as Valosin Containing Protein, Matrin-3, and a serine palmitoyltransferase subunit contribute to the pathogenesis of ALS, shedding light on overlapping pathways and pleiotropic effects on other diseases. In addition to her extensive research endeavors, Dr. Johnson has made significant strides in HIV research at the Walter Reed Army Institute of Research, utilizing novel multiomics technologies to investigate interactions between the retrovirus and host cells. Her recent experience in immunology includes serving as a Patent Examiner for the United States Patent and Trademark Office, where she evaluated inventions for cancer immunotherapy. Dr. Johnson is widely recognized in the field of molecular genetics for her expertise and numerous scientific breakthroughs, contributing significantly to our understanding of complex disorders. She is deeply passionate about research and serves as a vocal advocate for diversity, equity, and inclusion (DEI) in science and healthcare. Dr. Johnson's exceptional talent lies in her ability to effectively communicate scientific concepts to both experts and the general public. Her lifelong commitment is to achieve DEI for genetic populations that have been traditionally understudied.

See Full Profile

Example neurodegeneration projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on neurodegeneration?

Development of Novel Therapeutics

An academic researcher in Neurodegeneration can collaborate with a pharmaceutical company to develop novel therapeutics for neurodegenerative diseases. They can contribute their expertise in understanding disease mechanisms and identifying potential drug targets. Through this collaboration, the company can benefit from the researcher's knowledge and insights to accelerate the drug discovery process.

Biomarker Development

Collaborating with a Neurodegeneration expert can help a biotech company in the development of biomarkers for early detection and monitoring of neurodegenerative diseases. The researcher can provide their expertise in identifying and validating biomarkers, which can aid in the diagnosis and treatment of these diseases. This collaboration can enhance the company's diagnostic capabilities and improve patient outcomes.

Clinical Trial Design and Analysis

An academic researcher specializing in Neurodegeneration can assist a pharmaceutical company in designing and analyzing clinical trials for potential neurodegenerative disease treatments. Their expertise in study design, patient selection, and data analysis can ensure the trials are conducted effectively and provide meaningful results. This collaboration can help the company in obtaining regulatory approval and advancing their drug candidates.

Neuroprotective Strategies

Collaborating with a Neurodegeneration expert can benefit a healthcare company in the development of neuroprotective strategies. The researcher can contribute their knowledge of disease mechanisms and potential therapeutic interventions to prevent or slow down neurodegeneration. This collaboration can lead to the development of innovative treatments and interventions that can improve patient outcomes and quality of life.

Personalized Medicine Approaches

Working with an academic researcher in Neurodegeneration can help a biotech company in developing personalized medicine approaches for neurodegenerative diseases. The researcher can provide insights into the genetic and molecular factors that contribute to disease progression and response to treatment. This collaboration can enable the company to develop targeted therapies and interventions tailored to individual patients, leading to more effective and personalized treatments.